Pharmacologic activation of PP2A by FTY720, but not FTY720-P (phosphorylated), reduced proliferation, inhibited clonogenic potential, and induced apoptosis in cells harboring the c-KIT mutation, that is frequently encountered in myeloid malignancies, especially AML (40). This evidence concerns the gene KIT and acute myeloid leukemia.